twoXAR Pharmaceuticals has built a development portfolio targeting 18+ different diseases. twoXAR’s unique approach to drug discovery combines steps from the traditional multi-step approach to R&D that severely limits the pace of drug discovery. This novel method – coupled with the company’s proprietary AI-driven platform – enables twoXAR to select a disease and initiate in vivo testing in months, instead of years.
Total Funding: $14.3M
Funding Stage: Series A
Business Stage: Growth
Market: N/A
Company Size: 1 to 25
Founded: 2014
